Background: There is little evidence to guide the establishment of treatment goals for moderate to severe psoriasis in the clinical setting.
Objective: We sought to compare Dermatology Life Quality Index scores and prescription topical medication use between patients with clear versus almost clear skin.
Methods: This was a multicenter cross-sectional study of 97 patients with clear skin and 441 patients with almost clear skin receiving current systemic therapy or phototherapy for a primary indication of plaque psoriasis evaluated at 1 of 10 US outpatient dermatology sites participating in the Dermatology Clinical Effectiveness Research Network.
Results: In adjusted analyses, patients with clear versus almost clear skin were more likely to report no impact of psoriasis on quality of life (relative risk 1.60; 95% confidence interval 1.37-1.86). Patients with clear versus almost clear skin were also more likely to report no prescription topical medication use in the preceding week (relative risk 2.08; 95% confidence interval 1.73-2.49).
Limitations: Cross-sectional design prohibits longitudinal assessment of outcomes.
Conclusions: Clinically important differences in quality of life and prescription topical medication use exist between patients with clear versus almost clear skin. Collectively, our results indicate that achievement of clear skin may be an important clinical distinction among patients with moderate to severe psoriasis.
Keywords: Dermatology Life Quality Index; Physician Global Assessment; Psoriasis Area and Severity Index; patient-reported outcome; psoriasis; quality of life.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.